| Literature DB >> 28239490 |
Abstract
Traumatic macular hole (TMH) is not a rare clinical condition, especially in young population. Its prognosis is of complexity and uncertainty, with a relatively high rate of spontaneous closure in some cases. Modern vitrectomy surgery plays an important role in the treatment of TMH, although the functional outcomes may be compromised by the concomitant retinal pathologies. Decision-making about the time of vitrectomy, especially in pediatric patients, remains to be clarified further.Entities:
Year: 2017 PMID: 28239490 PMCID: PMC5292388 DOI: 10.1155/2017/1748135
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Literature review of case reports on spontaneous closure of TMH.
| References | Patient's age (yrs) | Closure time after injury | Hole size | Initial VA | Final VA |
|---|---|---|---|---|---|
| Nunode et al., 1983 [ | 11 | 15 days | 0.2 DD | CF | 0.1 |
|
| |||||
| Kusaka et al., 1997 [ | 12 | 4 months | 0.1 DD | 0.5 | 1.0 |
| 18 | 4 months | 0.1 DD | 0.5 | 1.0 | |
| 19 | 3 months | 0.1 DD | 0.2 | 1.0 | |
|
| |||||
| Murakami et al., 1998 [ | 12 | 3 months | 0.2 DD | 0.03 | 0.5 |
| 10 | 3 months | 0.1 DD | 0.3 | 0.6 | |
|
| |||||
| Parmar et al., 1999 [ | 25 | 15 days | 370 | CF | 0.1 |
|
| |||||
| Mitamura et al., 2001 [ | 17 | 12 months | 0.2 DD | 0.29 | 1.0 |
| 13 | 3 months | 0.2 DD | 0.2 | 1.0 | |
| 12 | 3.5 months | 0.1 DD | 0.28 | 1.0 | |
| 8 | 4 months | 0.2 DD | 0.1 | 1.0 | |
| 17 | 11 months | 0.1 DD | 0.1 | 0.8 | |
| 13 | 1 month | 0.2 DD | 0.2 | 0.4 | |
| 15 | 3 months | 0.1 DD | 0.67 | 1.0 | |
|
| |||||
| Yamada et al., 2002 [ | 11 | 18 weeks | 0.2 DD | 0.2 | 1.5 |
| 19 | 4 months | 0.2 DD | 0.1 | 0.67 | |
| 15 | 6 months | 0.17 DD | 0.1 | 0.67 | |
|
| |||||
| Yeshurun et al., 2002 [ | 15 | 5 weeks | 600 | 0.08 | 0.1 |
|
| |||||
| Menchini et al., 2003 [ | 56 | 2 months | 180 | 0.2 | 0.67 |
|
| |||||
| Carpineto et al., 2005 [ | 10 | 18 weeks | 200 | 0.1 | 0.8 |
|
| |||||
| Lai et al., 2005 [ | 24 | 6 weeks | 100 | 0.17 | 1.0 |
|
| |||||
| Chen et al., 2008 [ | 25 | 2 weeks | n/a | 0.01 | 0.7 |
| 2 weeks | n/a | 0.01 | 0.9 | ||
|
| |||||
| Valmaggia et al., 2009 [ | 9 | 3 weeks | 178 | 0.04 | 0.5 |
|
| |||||
| Nasr et al., 2011 [ | 50 | 17 days | n/a | 0.03 | 0.16 |
|
| |||||
| de Filippi Sartori et al., 2012 [ | 15 | 2 months | n/a | 0.2 | 0.8 |
|
| |||||
| Karaca et al., 2014 [ | 21 | 1 month | n/a | CF | CF |
|
| |||||
| Faghihi et al., 2014 [ | 20 | 2 months | n/a | 0.04 | 0.04 |
| 15 | 6 months | n/a | 0.1 | 0.4 | |
| 25 | 2 months | n/a | 0.06 | 0.6 | |
| 55 | 1 month | n/a | 0.3 | 0.4 | |
Literature review of case series reports on spontaneous closure rate of TMH.
| References | Number of cases | Mean age (yrs) | Observation time (month) | Closure rate | Closure time after injury (month) |
|---|---|---|---|---|---|
| Mizusawa et al., 1996 [ | 10 | n/a | 8 | 10% | 9 |
| Tomii et al., 1999 [ | 6 | n/a | 3 or more | 67% | 2.9 (0.5–5) |
| Yamashita et al., 2002 [ | 18 | n/a | 8.4 (4–12) | 44% | 1.7 (0.27–4) |
| Li et al., 2008 [ | 28 | 30 | 14 (3–131) | 10.70% | 4.5 |
| Yuan et al., 2015 [ | 21 | 26 | 12 | 33% | 1.7 |
| Chen et al., 2015 [ | 27 | 26 | 9 (6–37) | 38% | n/a |
| Miller et al., 2015 [ | 28 | 21 | 26.4 | 39% | 1.3 (0.4–15.7) |
Literature review of reports on vitrectomy outcomes for TMH.
| References | Number of cases | Mean age (yrs) | Adjuvants | Tamponades | Anatomic success | Functional success# |
|---|---|---|---|---|---|---|
| Rubin et al., 1995 [ | 12 | 15 | TGF- | C3F8 | 67% | 67% |
| García-Arumí et al., 1997 [ | 14 | 22 | Platelet concentrate | SF6 | 93% | 93% |
| Barreau et al., 1997 [ | 4 | 17 | Platelet concentrate | C3F8 | 75% | 50% |
| Margherio et al., 1998 [ | 4 | 13 | Autologous plasmin | C3F8 | 100% | 100% |
| Amari et al., 1999 [ | 23 | 27 | None | SF6 | 70% | 87% |
| Chow et al., 1999 [ | 16 | 25 | Autologous plasmin | C3F8 | 94% | 69% |
| Johnson et al., 2001 [ | 25 | 23 | Serum or none | C3F8 | 96% | 84% |
| Kuhn et al., 2001 [ | 17 | 26 | None | SF6 | 100% | 94% |
| Wachtlin et al., 2003 [ | 4 | 13 | Platelet concentrate | SF6 | 100% | 100% |
| Wu et al., 2007 [ | 13 | 10 | Plasmin | C3F8 or sio | 92% | 92% |
| Ghoraba et al., 2012 [ | 22 | 27 | None | C3F8 or sio | 82% | n/a |
| Azevedo et al., 2013 [ | 4 | 12 | None | Gas | 100% | 75% |
| Hou and Jiang, 2013 [ | 54 | 27 | Platelet concentrate | SF6/C2F6/C3F8 | 89% | 52% |
| Miller et al., 2015 [ | 11 | 21 | None | Gas or sio | 45% | n/a |
| Yuan et al., 2015 [ | 26 | 32 | None | C3F8 | 69% | 27% |
| Abou Shousha, 2016 [ | 12 | 23 | None | SF6 | 100% | n/a |
With one operation; #2 lines' visual acuity improvement; sio: silicone oil.